Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: Statistical evaluation based on the FFCD 9203 trial

Annals of Oncology

Volumn 21, Issue 3, 2009, Pages 518-524

  Methy, N ^a   Bedenne, L ^a,b   Conroy, T ^c   Bouche O ^d   Chapet, O ^e   Ducreux, M ^f   Gerard J P ^g   Bonnetain, F ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b HÔPITAL DU BOCAGE   (France)

^c CENTRE ALEXIS VAUTRIN   (France)

^d SERVICE DE DERMATOLOGIE   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Chemoradiation; Clinical trial; Radiation; Rectal neoplasms; Surrogate end points

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; TUMOR REGRESSION;

EID: 77949605556     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp340     Document Type: Article

References (30)

1. Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist 2008; 13 (Suppl 2): 19-21.
2. Gerard JP, Conroy T, Bonnetain F et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24: 4620-4625.
3. Bosset JF, Collette L, Calais G et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-1123.
4. Abrams J. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: a commentary. J Clin Oncol 2005; 23: 8564-8565.
5. Ellenberg S, Hamilton JM. Surrogate endpoints in clinical trials: cancer. Stat Med 1989; 8: 405-413.
6. Di Leo A, Buyse M, Bleiberg H. Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11. Ann Oncol 2004; 15: 545-549.
7. Buyse M, Burzykowski T, Carroll K et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007; 25: 5218-5224.
8. Glynne-Jones R, Mawdsley S, Pearce T, Buyse M. Alternative clinical end points in rectal cancer-are we getting closer? Ann Oncol 2006; 17: 1239-1248.
9. Weir CJ, Walley RJ. Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Stat Med 2006; 25: 183-203.
10. Burzykowski T, Molenberghs G, Buyse M. The Evaluation of Surrogate Endpoint. New York: Springer 2005.
11. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125: 605-613.
12. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8: 431-440.
13. Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 1992; 11: 167-178.
14. Buyse M, Molenberghs G. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 1998; 54: 1014-1029.
15. Glynne-Jones R, Mawdsley S, Novell JR. The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language. Colorectal Dis 2006; 8: 800-807.
16. Glynne-Jones R, Anyamene N. Just how useful an endpoint is complete pathological response after neoadjuvant chemoradiation in rectal cancer? Int J Radiat Oncol Biol Phys 2006; 66: 319-320.
17. Glynne-Jones R, Wallace M, Livingstone JI, Meyrick-Thomas J. Complete clinical response after preoperative chemoradiation in rectal cancer: is a "wait and see" policy justified? Dis Colon Rectum 2008; 51: 10-19; discussion 19-20.
18. Hartley A, Ho KF, McConkey C, Geh JI. Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials. Br J Radiol 2005; 78: 934-938.
19. Kerr SF, Norton S, Glynne-Jones R. Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity without compromising prognosis. Br J Surg 2008; 95: 1534-1540.
20. Kassaï B, Gueyffier F, Boissel JP. Critères intermédiaires et critères de substitution. Médecine Thérapeutique 2006; 12: 96-103.
21. Panageas KS, Ben-Porat L, Dickler MN et al. When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst 2007; 99: 428-432.
22. Baker SG, Kramer BS. A perfect correlate does not make a surrogate. BMC Med Res Methodol 2003; 3: 16.
23. Buyse M, Molenberghs G, Burzykowski T et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000; 1: 49-67.
24. Berger VW. Does the Prentice criterion validate surrogate endpoints? Stat Med 2004; 23: 1571-1578.
25. Collette L, Buyse M, Burzykowski T. Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed! J Clin Oncol 2007; 25: 5673-5674; author reply 5674.
26. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
27. Sargent DJ, Wieand HS, Haller DG et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005; 23: 8664-8670.
28. Sargent DJ, Patiyil S, Yothers G et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 2007; 25: 4569-4574.
29. Burzykowski T, Buyse M, Yothers G et al. Exploring and validating surrogate endpoints in colorectal cancer. Lifetime Data Anal 2008; 14: 54-64.
30. Yothers G. Toward progression-free survival as a primary end point in advanced colorectal cancer. J Clin Oncol 2007; 25: 5153-5154.